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Objective: To investigate whether an early 3-week postpartum visit in addition to the standard 
6-week visit increases LARC initiation by 8 weeks postpartum compared to the routine 6-week 
visit alone. 
Study Design: We enrolled pregnant and immediate postpartum women into a prospective 
randomized, non-blinded trial comparing a single 6-week postpartum visit (routine care) to two 
visits at 3 and 6 weeks postpartum (intervention), with initiation of contraception at the 3-week 
visit, if desired. All participants received structured contraceptive counseling. Participants 
completed surveys in-person at baseline and at the time of each postpartum visit. A sample size 
of 200 total participants was needed to detect a 2-fold difference in LARC initiation (20% vs. 
40%). 
Results: Between May 2016 and March 2017, 200 participants enrolled; outcome data are 
available for 188. The majority of LARC initiation occurred immediately postpartum (25% of the 
intervention arm and 27% of the routine care arm). By 8 weeks postpartum, 34% of participants 
in the intervention arm initiated LARC, compared to 41% in the routine care arm (p=0.35). 
Overall contraceptive initiation by 8 weeks was 83% and 84% in the intervention and routine 
care arms, respectively (p=0.79). There was no difference between the arms in the proportion 
of women who attended at least one postpartum visit (70% vs. 74%, p=0.56).  
Conclusion: The addition of a 3-week postpartum visit to routine care does not increase LARC 
initiation by 8 weeks postpartum. The majority of LARC users desired immediate rather than 
interval postpartum initiation.  
Clinical Trial Registration:  Clinicaltrials.gov NCT02769676 
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Implications: The addition of a 3-week postpartum visit to routine care does not increase LARC 
or overall contraceptive initiation by 8 weeks post-partum when the option of immediate 
postpartum placement is available. The majority of LARC users desired immediate rather than 
interval postpartum initiation. 
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1. Introduction 
Most women return to sexual activity and ovulation before the 6-week postpartum 
visit(1). Therefore, it is recommended that women not exclusively breastfeeding initiate 
contraception by 3 weeks postpartum(1). However, only 20% of women use contraception in 
the month following delivery(2). Immediate postpartum (IPP) initiation of long acting reversible 
contraception (LARC) is a successful strategy(3, 4), but not all patients desire IPP initiation, 
there is a higher expulsion rate with IPP intrauterine device (IUD) placement(5), and access to 
IPP LARC is limited. Strategies for improving postpartum LARC access must address the multiple 
post-discharge barriers(6-11).  
A common barrier to LARC initiation at a 6-week visit is difficulty excluding 
pregnancy(12), prompting a second visit, thus reducing the likelihood of initiating any 
method(13). LARC initiation before 4 weeks postpartum eliminates this concern, as pregnancy 
can always be ruled out(14). Additionally, many women lose public health insurance 6-8 weeks 
postpartum(15), making LARC unaffordable. Changing the model of postpartum care to include 
a 3-week visit with LARC initiation, if desired, has the potential to reduce these barriers.  
Studies show 2-3 week postpartum IUD insertion is feasible and acceptable with lower 
expulsion rates compared to reported rates after IPP insertion(16-18). However, variable 
methodology and populations and lack of availability of IPP insertion leave unanswered 
questions. One option is to schedule one early visit, but this may miss an opportunity to 
address issues that arise later. Adding an early visit to routine care is one strategy that 
addresses barriers to LARC access and provides comprehensive care.  We hypothesized that 
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two planned visits, at 3- and 6-weeks postpartum, compared to one 6-week visit, would 
increase LARC initiation by 8 weeks postpartum.  
 
2. Materials and Methods 
 This study was conducted from May 2016 to March 2017 at a tertiary academic medical 
center in St. Louis, Missouri. We obtained Institutional Review Board approval and registered at 
ClinicalTrials.gov (NCT02769676) prior to recruitment. We followed the Consolidated Standards 
of Reporting Trials (CONSORT) guidelines for reporting randomized trials.  
We performed a parallel, randomized, non-blinded trial in which participants were 
randomized with 1:1 allocation to two arms: the routine care arm participants were scheduled 
for the routine 6-week postpartum visit, while the intervention arm participants were 
scheduled for visits at 3- and 6-weeks postpartum. We initially recruited from the inpatient 
postpartum service, but due to slow enrollment we additionally recruited antepartum women 
in the outpatient obstetrics clinic. Research assistants screened potential participants during 
postpartum hospitalization or at routine antepartum visits and willing participants underwent 
written informed consent. We included women aged 14-45, ≥36 weeks’ gestation or 
postpartum, planning to deliver or delivered at our hospital, and planning to attend postpartum 
care at the outpatient clinic.  We excluded women who were unable to be approached, 
incarcerated or non-English speaking. Participants recruited postpartum were excluded if they 
already received IPP LARC or sterilization or if they experienced abortion, stillbirth, or neonatal 
death in this pregnancy.  
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After enrollment, all participants received contraceptive counseling based on the 
Contraceptive CHOICE Project model,(19) including information about all methods in order of 
effectiveness. Participants were block randomized in blocks of six and allocation was revealed 
using sequentially numbered sealed opaque envelopes. Participants in the routine care arm 
were scheduled for a 6-week postpartum visit, and a post-operative visit at 2-3 weeks for those 
who underwent cesarean delivery, per our institution’s practice. The post-operative visit did 
not routinely include contraceptive initiation, but may at the discretion of the provider. 
Participants in the intervention arm were scheduled for visits at 3- and 6-weeks postpartum. 
For those who underwent cesarean delivery, the post-operative and 3-week visits were 
combined. The 3-week visit in the intervention arm included initiation of contraception, 
including LARC, if desired, along with standard postpartum care. Early visits were scheduled 
with residents, who inserted LARC under the supervision of generalists or family planning 
providers. Ultrasound-guidance was available, but never used. The 6-week visits were 
scheduled with nurse practitioners or residents. Participants received appointment reminders 
via phone, text, or email, depending on preference.  
Our primary outcome was LARC initiation by 8 weeks postpartum. Secondary outcomes 
were overall contraceptive initiation by 8 weeks postpartum and postpartum visit attendance. 
Baseline and outcome data were determined through electronic medical record (EMR) review 
and participant report, which was obtained via in-person questionnaire at each visit or by 
telephone within 1 month of an unattended visit. No discrepancies were noted between EMR 
and participant report. Data collected included contraceptive use, initiation timing, and visit 
attendance. Participants who discontinued or switched methods were classified based on final 
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method by 8 weeks. For participants who did not attend the 6-week visit and were 
unreachable, we assumed their method was the most recently used method and included them 
in primary analysis based on allocated group. Participants who attended visits at the wrong 
timing were analyzed based on their allocated group. Participants for whom we had no contact 
after enrollment were excluded from the analysis. Participants received gift cards as follows: 
$20 at enrollment, $20 for attending the additional visit, and $10 for each survey.  
Data collection/management was performed using REDCap electronic data tools. 
Analyses were performed using SAS (Version 9.4, SAS Institute Inc., Cary, NC). All tests were 
two-sided with p-value <0.05 deemed statistically significant. Baseline characteristics were 
compared between the two arms using Student’s t-test, Chi-square or Fisher’s exact test, as 
appropriate. Primary and secondary outcomes were compared between the two arms using 
Chi-square test.   
Using billing data, we estimated an outpatient postpartum LARC initiation rate of 20%. 
We proposed that a 2-fold increase to 40% would be clinically significant. Using 80% power to 
detect this difference, given an alpha (type 1) error of 0.05, and accounting for 20% loss to 
follow-up, we estimated a sample size of 100 per arm.  
Prior to study initiation, there was no insurance coverage for IPP LARC and it was rarely 
provided. After study initiation, Missouri State Medicaid authorized reimbursement for IPP 
LARC, and this practice was rapidly implemented. In order to evaluate the isolated effect of the 
post-discharge intervention, we performed post hoc analyses excluding participants who 
received IPP LARC or sterilization. Relative risks and 95% confidence intervals were generated 
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to estimate the effects of assigned arm and attendance to an early postpartum visit, 
respectively, on LARC and overall contraceptive initiation. 
3. Results 
 A total of 200 patients were enrolled and randomized, 99 in the intervention arm and 
101 in the routine care arm (Figure 1). Three were excluded post-randomization due to 
ineligibility: two enrolled postpartum in error (one already received an IP  IUD and one did not 
plan to attend our clinic) and one enrolled antepartum but underwent hysterectomy. Four 
participants in the intervention and five in the routine care arm were lost to follow-up, leaving 
188 for analysis (93 in the intervention, 95 in the routine care arm). The two arms were similar 
(Table 1), including predominantly young, single, multiparous, black, low-income women, using 
Medicaid insurance, with a high rate of unintended pregnancy, consistent with our urban 
hospital-based clinic population. In each arm, approximately 1/3 of participants enrolled 
antepartum and 2/3 enrolled postpartum. At enrollment, 94% desired postpartum 
contraception; 77% preferred initiation as soon as possible, while 15% preferred initiation at 
the 6-week visit. After contraceptive counseling, approximately 40% in each arm planned to 
initiate LARC (see Table 1 for method breakdown). On enrollment, when queried about 
preference for postpartum visit timing, 62% preferred within 4 weeks, 28% preferred in 6 
weeks, and only 2% preferred multiple visits.  Preference for a visit within 4 weeks did not differ 
based on parity (multiparous 58% vs. nulliparous 73%, p=0.086), but differed slightly based on 
enrollment timing (antepartum 52% vs. postpartum 67%, p=0.047). 
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 The two arms were similar in rate of LARC initiation by 8 weeks postpartum (34% 
[32/93] in the intervention vs. 41% [39/95] in the routine care arm; p=0.35) (Table 2). Most 
LARC users chose IPP initiation (25% [23/93] of the intervention arm [8 IUDs and 15 implants] 
and 27% [26/95] of the routine care arm arm [7 IUDs and 19 implants]). In the intervention arm, 
4% (4/93) initiated LARC at the 3-week visit (3 IUDs and one implant) and 5% (5/93) initiated 
LARC at the 6-week visit (4 IUDs and one implant). In the routine care arm, 3% (3/95) initiated 
LARC at an early post-operative visit (4 implants) and 11% (10/95) initiated LARC at the 6-week 
visit (4 IUDs and 6 implants). One participant in the intervention arm and 3 in the routine care 
arm received injectable contraception IPP, then initiated LARC between 5-7 weeks postpartum. 
IUD expulsions were rare; only one participant in the routine care arm who received immediate 
post-cesarean IUD insertion experienced a partial expulsion 10 days postpartum. Overall 
contraceptive initiation by 8 weeks also was similar between the two arms (83% [77/93] in the 
intervention vs. 84% [80/95] in the routine care arm; p=0.79). Most reversible non-LARC users 
also initiated use prior to hospital discharge (24% [22/93] of the intervention and 25% [24/95] 
of the routine care arm).  
Only 46% [43/93] of the intervention arm attended the 3-week postpartum visit. The 
two arms were similar in attendance to at least one visit (70% [65/93] in the intervention vs. 
74% [70/95] in the routine care arm, p=0.56) and attendance to the 6-week visit (54% [50/93] in 
the intervention vs. 65% [62/95] in the routine care arm, p=0.11) (Table 3). Only 30% [28/93] of 
the intervention arm and 17% [16/95] of the routine care arm attended two visits. Receiving IPP 
LARC or sterilization did not impact postpartum visit attendance (66% [38/58] of women who 
received IPP LARC or sterilization attended at least one visit vs. 75% [98/130] of women who 
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did not, p=0.16).  Approximately 90% of women who attended a visit reported somewhat or 
complete visit satisfaction, with similar ratings for each arm and for both early and routine 
postpartum visits.   
To evaluate the effect of the post-discharge intervention we performed post hoc 
analyses excluding participants who received IPP LARC or sterilization. This cohort includes 130 
participants, 66 in the intervention and 64 in the routine care arm. There was no difference in 
LARC initiation (14% [9/66] in the intervention vs. 20% [13/64] in the routine care arm, p=0.31) 
or overall contraceptive initiation (76% [50/66] in the intervention vs. 77% [49/64] in the 
routine care arm, p=0.91). Within this cohort we also explored whether attendance to an early 
visit impacted LARC or overall contraceptive initiation; 36% (47/130) attended an early visit and 
64% (83/130) did not. There was no difference in LARC initiation (21% [10/47] of participants 
who attended an early visit vs. 14% [12/83] of those who did not; p=0.32). However, 
participants who attended an early visit were more likely to initiate any contraceptive method 
by both 4 weeks (66% [31/47] vs. 41% [34/83]; RR 1.61, 95% CI 1.16-2.24) and 8 weeks 
postpartum (87% [41/47] vs. 70% [58/83]; RR 1.25, 95% CI 1.04-1.49). 
Because 27% of the routine care arm also attended an early postoperative visit after 
cesarean delivery, we performed a post hoc analysis excluding participants who underwent 
cesarean. There was still no difference in initiation of LARC (31% [20/65] vs. 38% [23/60], 
p=0.37) or any contraception (77% [50/65] vs. 80% [48/60], p=0.68) or attendance to at least 
one postpartum visit (65% [42/65] vs. 67% [40/60], p=0.81).  
4. Discussion 
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 We found that planned 3- and 6-week postpartum visits compared to a single, routine 6-
week visit did not increase LARC or overall contraceptive initiation rates or attendance to at 
least one postpartum visit. Among the participants who did not receive IPP LARC or 
sterilization, there was still no difference in LARC or overall contraceptive initiation between 
the two groups.  However, participants who attended an early postpartum visit were more 
likely to initiate contraception by both 4 and 8 weeks postpartum, compared to those who did 
not attend an early visit. The majority of LARC and overall contraceptive initiation occurred 
immediately postpartum and we had high rates of contraceptive use by 8 weeks postpartum 
(>80% for each group). 
Recent studies have evaluated the feasibility, safety and acceptability of early 
postpartum IUD insertion (16, 17). Zerden et al. found that IUD insertion at 2-3 weeks 
postpartum had high patient acceptability and method continuation rates and a lower 
expulsion rate compared with published reports of IPP insertion(16). Baldwin, et al. randomized 
women to 3 or 6-week postpartum IUD insertion and found similarly high IUD use (75% vs. 80%) 
at 3 months postpartum in both groups (17). Together with our findings of high uptake of IPP 
contraception, this evidence indicates that the timing of initiation may not be as important as 
the availability of multiple opportunities for postpartum LARC services.  
Despite most women expressing a preference for a visit within 4 weeks, only 46% of the 
intervention group attended the 3-week visit. However, our findings suggest that attending an 
earlier visit may improve overall contraceptive initiation compared to attending only a later 
postpartum visit. The results from Baldwin, et al. support this, as they found that women 
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randomized to 3-week insertion were more likely to receive an IUD by 45 days postpartum and 
prior to resuming intercourse,(17) indicating that planning for earlier initiation may help 
circumvent barriers. Multiple socioeconomic and cultural factors may influence ability to attend 
a postpartum visit and interventions to improve postpartum contraceptive use may have 
limited success in women who have difficulty attending visits (20-22). This reinforces the 
importance of the availability of IPP LARC, and indicates the need to individualize postpartum 
care, including visit timing. 
The strengths of this study are the randomized trial design, implementation within a 
real-world setting, and minimal loss to follow-up. The main limitation was the unexpected 
implementation of IPP LARC during our study, resulting in high rates of IPP LARC initiation. Our 
intervention was designed to provide the most benefit for women discharged without an 
effective method, and we suspect that the high rate of IPP LARC uptake mitigated the potential 
benefit of an early postpartum visit. Therefore the results of this study may not be 
generalizable to populations without access to IPP LARC. The availability of IPP LARC increased 
LARC use above the estimated 20% baseline. Additionally, 27% of participants in the routine 
care arm attended an early post-operative visit following cesarean delivery and some 
participants initiated contraception at this visit, making the routine care arm more similar to 
the intervention. These factors may have biased our study towards showing no difference 
between the two arms. Study participation may have increased LARC use due to the additional 
counseling and postpartum visit attendance due to receiving appointment reminders, neither 
of which are institutional standard of care.  
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There has been increasing appreciation for the needs of postpartum women, (23) but 
we need to continue to optimize their care, including contraceptive initiation. Our study 
indicates that when available, most women prefer IPP contraceptive initiation. For those who 
don’t, planning for an early postpartum visit may not be sufficient, but attending an early visit 
may be beneficial for improving contraceptive initiation. Further research should evaluate how 
to improve access to highly effective contraception for women across the postpartum phase, 
including the early postpartum period. 
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Table 1:  Comparison of participant baseline characteristics by study arm: intervention  
(3 and 6 week postpartum visits) versus routine care shows no differences between  
the two arms. 
 
 
 
 
Characteristic Intervention Arm 
(n=93) 
Routine Care Arm 
(n=95) 
Age, in years 26.0±5 25.3±5 
Race   
  Black 84 (90.3) 84 (88.4) 
  White 5 (5.4) 10 (10.5) 
  Other 4 (4.3) 1 (1.1) 
Ethnicity   
   Non-Latina 84 (90.3) 88 (92.6) 
   Latina 9 (9.7) 7 (7.4) 
Relationship status   
  Single/never married 51 (54.8) 56 (58.9) 
  Married/cohabitating 38 (41.0) 37 (38.9) 
  Separate/divorced/widowed 3 (3.2) 2 (2.1) 
  Missing 1 (1.1) 0 
Previous delivery 74 (79.6) 72 (75.8) 
Educational attainment   
   Less than high school 16 (17.2) 12 (12.6) 
   High school/GED 35 (37.6) 47 (49.5) 
   Some college/associates degree 32 (34.4) 31 (32.6) 
   Vocational/technical school 5 (5.4) 4 (4.2) 
   College degree 5 (5.4) 1 (1.1) 
Employment status   
    Working full-time 28 (30.1) 33 (34.7) 
    Working part-time 17 (18.3) 14 (14.7) 
    Unemployed 32 (34.4) 30 (31.6) 
    Disabled/sick leave/other 11 (11.8) 12 (12.6) 
    Full-time student 5 (5.4) 6 (6.3) 
Currently receiving public assistance 81 (87.1) 86 (90.5) 
Trouble paying for basic necessities 31 (33.3) 36 (37.9) 
   Missing 2 (2.2) 3 (3.2) 
Mode of delivery    
   Vaginal  65 (70.0) 60 (63.2) 
   Cesarean 28 (30.1) 35 (36.8) 
Prior unintended pregnancy 68 (73.1) 73 (76.8) 
Current unintended pregnancy 59 (63.4) 64 (68.1) 
    Missing 0 1 (1.1) 
Desires future pregnancy   
   No 53 (57.0) 53 (55.8) 
   Yes 25 (26.9) 32 (33.7) 
   Unsure/Ambivalent 15 (16.1) 10 (10.5) 
Desired timing of future pregnancy   
  In 1-2 years 4 (10.0) 2 (4.8) 
  In >2 years 33 (82.5) 35 (83.3) 
  Unsure 3 (7.5) 4 (9.5) 
   Missing 0 1 (2.4) 
Planned postpartum contraceptive method*   
LARC 41 (44.1) 39 (41.1) 
   IUD 15 (16.1) 14 (14.7) 
   Implant 26 (28.0) 25 (26.3) 
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Values are expressed as mean±standard deviation for continuous variables or  
number of subjects (percentage) for categorical variables.  
GED = General Education Development/Diploma 
*Total >100% due to multiple possible responses 
LARC = long-acting reversible contraception 
IUD = intrauterine device 
Implant = subdermal contraceptive implant 
**Reversible non-LARC methods = Depo-medroxyprogesterone acetate (DMPA),  
    oral contraceptive pills, contraceptive patch, or contraceptive ring. 
 
  
Reversible non-LARC methods** 27 (29.0) 29 (30.5) 
Permanent sterilization 15 (16.1) 15 (15.8) 
None/Other/Unsure 16 (17.2) 16 (16.8) 
Preference for postpartum visit timing   
1-2 weeks 30 (30.9) 23 (24.2) 
3-4 weeks 35 (37.6) 28 (29.5) 
6 weeks 11 (11.8) 41 (43.2) 
More than 1 visit 4 (4.3) 0 
No preference/unsure 13 (14.0) 3 (3.2) 
Enrollment timing/site   
Antepartum/outpatient 34 (36.6) 33 (34.7) 
Postpartum/inpatient 59 (63.4) 62 (65.3) 
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Table 2:  Comparison of participant contraceptive method initiation by study arm: intervention (3  
and 6 week postpartum visits) versus routine care. 
  Intervention Arm 
(n=93) 
Routine Care Arm 
(n=95) 
p-value** 
Immediate Postpartum      
 LARC 23 (24.7) 26 (27.4) 
    Intrauterine device 8 (8.6) 7 (7.4)  
    Implant 15 (16.1) 19 (20.0)  
Reversible non-LARC* 22 (23.7) 24 (25.3)  
Sterilization 4 (4.3) 5 (5.3) 
 Cumulative total use 49 (52.7) 55 (57.9) 0.47 
Discharge to ≤ 4 Weeks Postpartum 
   LARC 4 (4.3) 3 (3.2) 
    Intrauterine device 3 (3.2) 0  
    Implant 1 (1.1) 4 (4.2)  
Reversible non-LARC* 11 (11.8) 2 (2.1)  
Sterilization 0 0 
 Cumulative total use 64 (68.9) 60 (63.2) 0.41 
>4 to 8 Weeks Postpartum 
   LARC 5 (5.4) 10 (10.5) 
    Intrauterine device 4 (4.3) 4 (4.2)  
    Implant 1 (1.1) 6 (6.3)  
Reversible non-LARC* 5 (5.4) 9 (9.5)  
Sterilization 3 (3.2) 1 (1.1) 
 LARC use by 8 weeks postpartum 32 (34.4) 39 (41.1) 0.35 
Any method use by 8 weeks postpartum 77 (82.8) 80 (84.2) 0.79 
Values are expressed as number of subjects (percentage).  
*Reversible non-LARC methods = Depo-medroxyprogesterone acetate (DMPA), oral contraceptive  
  pills, contraceptive patch, or contraceptive ring. 
**All p-values obtained by Chi-square testing  
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Table 3:  Comparison of postpartum visit attendance by study arm: intervention (3 and 6 week postpartum 
visits) versus routine care. 
 Intervention Arm 
(n=93) 
Routine Care Arm 
(n=95) 
p-value* 
Early postpartum/postoperative visit 43 (46.2) 26 (27.4) 0.007 
6-week postpartum visit 50 (53.7) 62 (65.3) 0.11 
Two visits 28 (30.1) 16 (16.8) 0.03 
At least one visit 65 (69.9) 70 (73.7) 0.56 
Values are expressed as number of subjects (percentage).  
*All p-values obtained by Chi-square testing 
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